Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YANELY MD PINEIRO PUEBLA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1750702189
CMS profile
1311571
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$220.06

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $220.06 6

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YANELY MD PINEIRO PUEBLA

NPI 1750702189 · CMS profile ID 1311571

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750702189?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750702189?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750702189?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1750702189?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $220.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $22.7111/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930264029 CMS
GlaxoSmithKline, LLC. $17.7710/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944591611 CMS
Alnylam Pharmaceuticals Inc. $24.8809/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926070821 CMS
Galderma Laboratories, L.P. $125.1305/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952290885 CMS
Novartis Pharmaceuticals Corporation $17.5004/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894233703 CMS
Genentech USA, Inc. $12.0702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950673631 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140.17 4
PY2021 $93.97 2
PY2022 $220.06 6
PY2023 $390.09 9
PY2024 $285.52 13
PY2025 $127.77 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $2,476,931.44 112
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $3,839,557.03 72
PY2023 Principal investigator $3,154,711.62 75
PY2022 Principal investigator $2,403,759.48 31
PY2021 Principal investigator $506,403.80 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $20,020.56 12/31/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929129
Principal investigator 1 Merck Sharp & Dohme LLC $3,238.08 12/31/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929131
Principal investigator 1 PFIZER INC. $1,755.00 12/29/2025 Non-covered Recipient Entity
Community Health Center Palm Springs
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228720623
Principal investigator 1 PFIZER INC. $4,969.70 12/23/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228726266
Principal investigator 1 PFIZER INC. $56,463.72 12/17/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716561
Principal investigator 1 PFIZER INC. $32,800.02 12/17/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228747688
Principal investigator 1 PFIZER INC. $18,884.86 12/16/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228746190
Principal investigator 1 Merck Sharp & Dohme LLC $103,216.00 12/15/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929127
Principal investigator 1 PFIZER INC. $15,300.00 12/12/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735574
Principal investigator 1 PFIZER INC. $1,521.00 12/05/2025 Non-covered Recipient Entity
Community Health Center Palm Springs
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729478
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228720131
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228720391
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228722830
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228724538
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725182
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725662
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725768
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725930
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725932
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731169
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731173
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731513
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731939
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732637
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732772
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735666
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735671
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736435
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736487
Principal investigator 1 PFIZER INC. $426.60 12/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228737865
Principal investigator 1 PFIZER INC. $10,798.62 11/26/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228715991
Principal investigator 1 PFIZER INC. $3,196.69 11/25/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728583
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228722502
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228723366
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724904
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725016
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725122
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725124
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228731389
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733015
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733949
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228738979
Principal investigator 1 PFIZER INC. $993.94 11/15/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228724444
Principal investigator 1 PFIZER INC. $3,127.74 11/13/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716563
Principal investigator 1 PFIZER INC. $265.20 11/13/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228723736
Principal investigator 1 PFIZER INC. $180.80 11/13/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228729326
Principal investigator 1 PFIZER INC. $26,836.38 11/11/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728157
Principal investigator 1 PFIZER INC. $125,109.60 11/05/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716485
Principal investigator 1 PFIZER INC. $9,522.57 10/30/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723288
Principal investigator 1 PFIZER INC. $2,133.00 10/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716453
Principal investigator 1 PFIZER INC. $378.75 10/20/2025 Non-covered Recipient Entity
Palm Springs Com Health
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716381
Principal investigator 1 PFIZER INC. $307.75 10/20/2025 Non-covered Recipient Entity
Palm Springs Com Health
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716383
Principal investigator 1 PFIZER INC. $46,715.18 10/11/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228730465
Principal investigator 1 PFIZER INC. $15,900.00 10/11/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228755094
Principal investigator 1 PFIZER INC. $757.50 09/25/2025 Non-covered Recipient Entity
Palm Springs Com Health
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228739778
Principal investigator 1 PFIZER INC. $615.50 09/25/2025 Non-covered Recipient Entity
Palm Springs Com Health
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228746833
Principal investigator 1 PFIZER INC. $11,927.28 09/24/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228758997
Principal investigator 1 PFIZER INC. $4,266.00 09/23/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716455
Principal investigator 1 PFIZER INC. $18,884.86 09/09/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771103
Principal investigator 1 PFIZER INC. $202.50 08/06/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228768038
Principal investigator 1 PFIZER INC. $66,593.98 08/01/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228766243
Principal investigator 1 PFIZER INC. $41,118.30 07/22/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228764457
Principal investigator 1 PFIZER INC. $28,407.43 07/11/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762828
Principal investigator 1 PFIZER INC. $12,899.25 07/09/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228763216
Principal investigator 1 PFIZER INC. $157,993.13 07/08/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771928
Principal investigator 1 PFIZER INC. $15,490.50 07/01/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228783548
Principal investigator 1 PFIZER INC. $18,552.26 06/26/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228792603
Recipient PFIZER INC. $3,200.00 06/25/2025 Covered Recipient Physician PF07926307 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760527
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $579.02 06/24/2025 Non-covered Recipient Entity
Angels Clinical Research Institute - Miami Lakes - Palm Springs - Ppds
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235999009
Principal investigator 1 PFIZER INC. $93,062.74 06/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228793410
Principal investigator 1 PFIZER INC. $6,049.65 06/14/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228778282
Principal investigator 1 PFIZER INC. $80,729.78 06/10/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228791313
Principal investigator 1 ABBVIE INC. $11,250.00 06/05/2025 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE INC
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE) Pibrentasvir (PIB) No dispute reported 06/30/2026 1202490353
Principal investigator 1 PFIZER INC. $26,758.25 05/30/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228783223
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706907
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228724520
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706729
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706909
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228760657
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228760660
Principal investigator 1 PFIZER INC. $64,406.75 05/15/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228776616
Principal investigator 1 PFIZER INC. $32,854.86 05/08/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228783568
Principal investigator 1 PFIZER INC. $10,000.00 04/16/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228780903
Principal investigator 1 PFIZER INC. $3,600.00 04/08/2025 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228793963
Principal investigator 1 PFIZER INC. $22,940.61 03/28/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228787693
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706727
Principal investigator 1 PFIZER INC. $189.80 03/23/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761558
Principal investigator 1 PFIZER INC. $4,036.50 03/21/2025 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228788159
Principal investigator 1 PFIZER INC. $43,796.59 03/20/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228779713
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706725
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228719981
Principal investigator 1 PFIZER INC. $13,187.00 03/04/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228788831
Principal investigator 1 Amgen Inc. $99.74 02/25/2025 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246639135
Principal investigator 1 PFIZER INC. $454.34 02/19/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228751706
Principal investigator 1 PFIZER INC. $12,397.32 02/14/2025 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228761552
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $192,323.36 02/12/2025 Non-covered Recipient Entity
Angels Clinical Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235999013
Principal investigator 1 PFIZER INC. $656.10 02/12/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228753815
Principal investigator 1 PFIZER INC. $317.00 02/10/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706905
Principal investigator 1 PFIZER INC. $726.10 02/10/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707083
Principal investigator 1 PFIZER INC. $726.10 02/10/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228760749
Principal investigator 1 PFIZER INC. $317.00 02/10/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761958
Principal investigator 1 PFIZER INC. $2,350.00 02/08/2025 Non-covered Recipient Entity
Palm Springs Comm Health Ctr
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228708098
Principal investigator 1 PFIZER INC. $38,697.75 02/05/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228758255
Principal investigator 1 PFIZER INC. $981.24 01/31/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228775528
Principal investigator 1 PFIZER INC. $837.08 01/31/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228785770
Principal investigator 1 PFIZER INC. $908.68 01/29/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800313
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $207,897.85 01/24/2025 Non-covered Recipient Entity
Elias Research Associates Llc
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997545
Principal investigator 1 PFIZER INC. $13,630.20 01/22/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228801515
Principal investigator 1 PFIZER INC. $45,906.92 01/15/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799923
Principal investigator 1 PFIZER INC. $7,840.00 01/15/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800871
Principal investigator 1 PFIZER INC. $60,837.27 01/08/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799814
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $544,585.65 01/03/2025 Non-covered Recipient Entity
Elias Research Associates Llc
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997547
Principal investigator 1 PFIZER INC. $33,927.66 01/01/2025 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799117